Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor

Bibliography

• Siegel R, DeSantis C, Virgo K, Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62(4):220-41
   PubMed Web of Science ®Google Scholar
• Matzkin H, Perito PE, Soloway MS. Prognostic factors in metastatic prostate cancer. Cancer 1993;72:3788-92
   PubMed Web of Science ®Google Scholar
• Bowen-Pope DF, Raines EW. History of discovery: platelet-derived growth factor. Arterioscler Thromb Vasc Biol 2011;31:2397-401
   PubMed Web of Science ®Google Scholar
• Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-312
   PubMed Web of Science ®Google Scholar
• Pietras K, Sjöblom T, Rubin K, PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439-43
   PubMed Web of Science ®Google Scholar
• Cao R, Björndahl MA, Religa P, PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004;6:333-45
   PubMed Web of Science ®Google Scholar
• Sitaras N, Sariban E, Bravo M. Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res 1988;48:1930-5
   PubMed Web of Science ®Google Scholar
• Fudge K, Wang CY, Stearns ME. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and gleason-graded human prostate adenocarcinomas. Mod Pathol 1994;7:549-54
   PubMed Web of Science ®Google Scholar
• Fudge K, Bostwick DG, Stearns ME. Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate 1996;29:282-6
   PubMed Web of Science ®Google Scholar
• Ko Y, Small EJ, Kabbinavar F, A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 2001;7:800-5
   PubMed Web of Science ®Google Scholar
• Chott A, Sun Z, Morganstern D, Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999;155:1271-9
   PubMed Web of Science ®Google Scholar
• Druker BJ, Shu T, Buchdunger E, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Cioffi CL, Law N, Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45
   PubMed Web of Science ®Google Scholar
• Uehara H, Kim SJ, Karashima T, Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003;95:458-70
   PubMed Web of Science ®Google Scholar
• Kim S-J, Uehara H, Yazici S, Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 2006;98:783-93
   PubMed Web of Science ®Google Scholar
• Pietras K, Rubin K, Sjöblom T, Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84
   PubMed Web of Science ®Google Scholar
• Pietras K, Stumm M, Hubert M, STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003;9:3779-87
   PubMed Web of Science ®Google Scholar
• Tiffany NM, Wersinger EM, Garzotto M, Beer TM. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology 2004;63:934-9
   PubMed Web of Science ®Google Scholar
• Mathew P, Thall PF, Jones D, Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004;22:3323-9
   PubMed Web of Science ®Google Scholar
• Lin A, Rini B, Derynck M. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer 2007;5:323-8
   PubMed Web of Science ®Google Scholar
• Nabhan C, Villines D, Valdez T V, Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. Br J Cancer 2012;107:592-7
   PubMed Web of Science ®Google Scholar
• Mathew P, Pisters LL, Wood CG, Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 2009;181:81-7; discussion 87
   PubMed Web of Science ®Google Scholar
• Lin AM, Rini BI, Weinberg V, A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 2006;98:763-9
   PubMed Web of Science ®Google Scholar
• Rao K, Goodin S, Levitt MJ, A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 2005;62:115-22
   PubMed Web of Science ®Google Scholar
• Bajaj GK, Zhang Z, Garrett-Mayer E, Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology 2007;69:526-31
   PubMed Web of Science ®Google Scholar
• Mathew P, Thall PF, Bucana CD, Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 2007;13:5816-24
   PubMed Web of Science ®Google Scholar
• Mathew P, Thall PF, Wen S, Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Br J Cancer 2008;99:1426-32
   PubMed Web of Science ®Google Scholar
• Morita S, Thall PF, Bekele BN, Mathew P. A Bayesian hierarchical mixture model for platelet derived growth factor receptor phosphorylation to improve estimation of progression-free survival in prostate cancer. J R Stat Soc Ser C Appl Stat 2009;59:19-34
   PubMed Web of Science ®Google Scholar
• Mathew P, Tannir N, Tu S-M, Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol 2011;68:889-96
   PubMed Web of Science ®Google Scholar
• Mathew P, Wen S, Morita S, Thall PF. Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. J Interferon Cytokine Res 2011;31:539-44
   PubMed Web of Science ®Google Scholar
• DePrimo SE, Huang X, Blackstein ME, Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res 2009;15:5869-77
   PubMed Web of Science ®Google Scholar
• Gillison TL, Appleman LJ, Friedland DM, Docetaxel and imatinib every 21 days for castration resistant prostate cancer: a phase II trial. J Clin Oncol 2009;27:e16086
   Google Scholar
• O'Sullivan S, Naot D, Callon K, Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007;22:1679-89
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Lin S-H. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-8
   Google Scholar
• Pinski J, Parikh A, Bova GS, Isaacs JT. Therapeutic implications of enhanced G 0/ G 1 checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 2001;61:6372-6
   PubMed Web of Science ®Google Scholar
• Gerhardt H, Semb H. Pericytes: gatekeepers in tumour cell metastasis? J Mol Med (Berlin, Germany) 2008;86:135-44
   PubMed Web of Science ®Google Scholar
• Xian X, Hakansson J, Stahlberg A, Pericytes limit tumor cell metastasis. J Clin Investig 2006;116:642-51
   PubMed Web of Science ®Google Scholar
• Cooke VG, LeBleu VS, Keskin D, Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012;21:66-81
   PubMed Web of Science ®Google Scholar
• Tu SM, Millikan RE, Mengistu B, Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357:336-41
   PubMed Web of Science ®Google Scholar
• Parker C, Heinrich D, O'Sullivan JM, Overall survival benefit and safety proflie of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 2012;30:abstract 8
   Google Scholar